Seer Inc. (NASDAQ:SEER) on Thursday said its Proteograph Product Suite will serve as the mass spectrometry-based workflow to profile the plasma proteome of 10,000 participants in the PRECISE-SG100K study, a large-scale population health initiative in Singapore.

Researchers will integrate the dataset generated using Seer's platform with outputs from Thermo Fisher Scientific Inc.'s (NYSE:TMO) Olink Reveal and Orbitrap Astral mass spectrometers, applying all to the same sample set to deepen proteomic insights.

Large-Scale Multi-Omics Ambition

PRECISE-SG100K is a multi-ancestry cohort targeting around 100,000 Singapore residents. The program combines genomic, proteomic, and clinical data across a diverse Asian population.

By incorporating Seer's Proteograph platform alongside imaging and phenotyping tools, the study aims to build a comprehensive multi-omic dataset.

The initiative will likely support precision health research, disease prevention strategies, and therapeutic discovery.

Adding deep plasma proteomics at this scale introduces a mechanistic layer linking genetic variation to protein activity and clinical outcomes.

Researchers see this as key for validating biomarkers, identifying drug targets, and improving population-level risk modeling.

Complementing Existing Proteomics Technologies

The Proteograph-Astral workflow has demonstrated the ability to deliver high-throughput and deep proteome coverage in large cohorts.

It enables quantification of thousands of proteins with peptide-level resolution.

This capability enhances mass spectrometry-based proteomics by validating and expanding findings from affinity-based platforms such as Olink Reveal.

The combined approach is increasingly viewed as complementary in large-scale studies.

Broader Applications In Disease Research

Researchers expect data generated from the Proteograph platform in cohorts like PRECISE-SG100K and studies involving Korea University to support biomarker discovery across multiple disease areas.

These include cardiometabolic, neurologic, and ophthalmic conditions, along with broader applications in drug target research.

The data may also help improve predictive models for disease risk and treatment response, particularly in underrepresented populations.

Recent Earnings

In February, Seer reported a fourth-quarter loss of 29 cents, beating the consensus of 32 cents. Sales jumped 5% to $4.20 million, below the consensus of $4.6 million.

Seer guided fiscal 2026 sales of $16 million-$18 million versus the consensus of $22.1 million.

Patent Trial and Appeal Board upheld claims continue to cover Seer's nanoparticle-based protein enrichment technology used across cells, tissues, and biofluids, against Bruker Corporation (NASDAQ:BKR) subsidiaries.

Seer Stock Price Activity: SEER shares closed at $1.69 on Wednesday, according to Benzinga Pro data.

Imagr via Shutterstock